Full-Time

HEVA Business Partner

Dupixent

Posted on 10/25/2024

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Position requires onsite presence in Cambridge, MA.

Category
Public Health
Biology & Biotech
Requirements
  • 5 years of experience in health economics, outcomes research, or a related field.
  • Strong communication skills, both verbal and written, including presentation skills. Significant experience making presentations to senior management is preferred. Publication in peer-reviewed journals.
  • Strong ability to partner with HEVA colleagues and other (i.e. non-HEOR) functional areas.
  • Entrepreneurial, team spirit and ability to develop creative solutions to complex problems.
  • Demonstrated experience in applying various HEOR methods. Understanding the principles of evidence-based medicine and clinical research.
  • Knowledge of global HTA processes and guidelines; experience with HTA submissions preferred.
  • Understanding of the legal and regulatory environment of the pharmaceutical industry, demonstrated integrity on work-related compliance considerations and solid ethics.
  • Advanced degree (PhD, MD, MS, MPH, or PharmD) in a scientific discipline.
  • English fluent, both written and oral.
Responsibilities
  • This role will be responsible for the design and execution of Health Economic and Outcomes Research (HEOR) research in the forms of economic modeling, database analysis, observational research, Clinical Outcomes Assessment (COA) development and validation, systematic literature review, evidence synthesis, value dossier development and other types of HEOR.
  • This role will set the HEOR evidence generation priorities for Dupixent indications under development and incorporate them into broader Sanofi planning documents such as the integrated evidence generation plan (IEGP).
  • This role will operate as part of a multi-functional global development team that is responsible for designing clinical research programs to meet the evidentiary standards of regulators, HTA organizations, reimbursement authorities, third-party payers and other organizations that review evidence relevant to Sanofi medicines.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi differentiates itself from competitors by its strong commitment to scientific innovation and a diverse product portfolio that includes prescription medicines and vaccines. Its goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Stage

IPO

Total Funding

$2B

Headquarters

Paris, France

Founded

1973

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's AI tool Muse optimizes patient recruitment for faster drug development.
  • Dupixent's EU approval expands market reach in pediatric eosinophilic esophagitis.
  • Strategic investment in Zucara Therapeutics enhances diabetes treatment portfolio.

What critics are saying

  • Increased competition from biotech startups in the rare disease sector.
  • Potential delays in drug development due to early-stage AI tools like Muse.
  • Safety concerns with tolebrutinib trials may lead to regulatory hurdles.

What makes Sanofi unique

  • Sanofi's Care4Rare program supports innovative solutions for rare diseases.
  • Partnership with BrightInsight accelerates drug development through digital health solutions.
  • Tolebrutinib's FDA Breakthrough Therapy designation highlights Sanofi's neurology innovation.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE